Newsroom

北京、カリフォルニア州アラメダ、台北--(BUSINESS WIRE)--（ビジネスワイヤ） -- バイオサイトジェン（Biocytogen、SSE：688796、HKEX：02315）およびAcepodia（6976：TT）は、二重特異性抗体薬物複合体（BsADC）プログラムの体系的な評価を可能にし、デュアルペイロード二重特異性抗体薬物複合体（BsAD2Cs）の開発をさらに推進することを目的とした、オプション契約およびライセンス契約を締結したことを発表しました。 本契約により、Acepodiaは、バイオサイトジェンから2件のBsADCプログラムについて、全世界における独占的ライセンスを取得するオプション権を付与されます。契約条件に基づき、バイオサイトジェンは、オプション料の一時金を受領する権利を有し、Acepodiaが当該オプションを行使した場合には、オプション行使料、開発、規制対応および商業化の各段階に応じたマイルストーン支払い、ならびに将来の製品売上高に基づくロイヤルティを受領することができます。なお、本契約の金銭的条件は開示されていません。 「今回の新しい合意は、有望な二重特...

北京、加州ALAMEDA和臺北--(BUSINESS WIRE)--(美國商業資訊)-- 百奧賽圖（北京）醫藥科技股份有限公司（以下簡稱「百奧賽圖」，SSE: 688796；HKEX: 02315）與育世博（6976.TT）今日宣布，雙方已達成一項選擇權與授權合約，旨在透過結構化的評估機制，對雙特異性抗體藥物偶聯物（BsADC）專案展開系統性評估，從而進一步加快雙特異性抗體雙藥物偶聯物（BsAD2C）的開發進程。 該協議將賦予育世博一項選擇權以獲得百奧賽圖兩項BsADC專案的全球獨家授權。百奧賽圖將有權獲得選擇權首付款；在育世博行使相關選擇權後，百奧賽圖還可獲得包括選擇權行使費、開發和監管里程碑付款、商業化里程碑付款以及銷售分成在內的後續款項。該協議的具體財務條款尚未揭露。 百奧賽圖董事長兼執行長沈月雷博士表示：「此次合作是在我們年初與育世博展開的共同開發合作基礎上進一步深化的結果。此前，雙方的合作重點聚焦於對有成藥潛力的雙特異性抗體及雙負載ADC候選專案的評估與篩選。根據已完成的臨床前研究成果，我們認為，將百奧賽圖的RenLite®全人共輕鏈抗體開發平台與育世博的抗體-雙藥物偶聯（A...

OAK RIDGE, Tennessee.--(BUSINESS WIRE)--La NASA invita tanto a los científicos noveles como a los más expertos a considerar las oportunidades de becas de su programa posdoctoral y a compartir la misión de la NASA de desarrollar avances en los campos de la ciencia, tecnología, aeronáutica y exploración espacial. La fecha límite para presentar las solicitudes para este ciclo de becas es el día 1 de marzo de 2026. Solicite más información o presente su candidatura para una beca del Programa Posdoc...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until March 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT), if they purchased or otherwise acquired the Company’s securities between July 18, 2024 and November 12, 2025, inclusive (the “C...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock. Awards were made to seventeen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Co...

LOS ANGELES--(BUSINESS WIRE)--Metropolitan Water District General Manager Shivaji Deshmukh issues the following statement regarding the U.S. Bureau of Reclamation’s release today of a Draft Environmental Impact Statement for post-2026 operations of Lake Powell and Lake Mead. “The release of today’s Draft EIS is yet another wake-up call that we need a consensus agreement supported by all water users that rely on the Colorado River. None of the five alternatives analyzed by the Bureau of Reclamat...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. Using its patented HYFT® Deep Data technology, MindWalk identified a functional pattern embedded in influenza biology that remains intact...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE:FCX) investors of the January 12, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Freeport securities between February 15, 2022 through September 24, 2025 (“the Class Period”). Follow the link below for more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is The Lawsuit About? The lawsuit alleg...

LOS ANGELES--(BUSINESS WIRE)--VRNS Investors Have Opportunity to Lead Varonis Systems, Inc. Securities Fraud Lawsuit with the Schall Law Firm...

NEW YORK--(BUSINESS WIRE)--KBRA releases the December 2025 issue of CMBS Trend Watch. U.S. CMBS finished the year at $125.8 billion—its highest issuance level since the global financial crisis (GFC)—with a year-over-year (YoY) increase of 18.6%, and in line with our 2025 forecast of $120 billion. Contributing to the increase was the continuing strong investor appetite for single-borrower (SB) deals at $91.1 billion, which accounted for 72.5% of issuance, with the remaining represented by condui...